Vardenafil orally disintegrating tablets (ODT) are a specific U.S. prescription dosage form, not simply a conventional vardenafil tablet that happens to dissolve quickly. The labeled ODT is a 10 mg product designed to disintegrate on the tongue. Its administration, pharmacokinetic exposure and certain drug-interaction restrictions differ from the standard film-coated formulation.
The most important distinction is direct: a 10 mg vardenafil ODT and a 10 mg film-coated vardenafil tablet are not interchangeable. The ODT produces higher systemic exposure than the corresponding film-coated tablet in label-based comparisons, so matching the milligram number is not adequate for pharmacy substitution or self-directed switching.
Staxyn was the former U.S. branded ODT and is no longer marketed as the original brand; separately labeled generic ODT products have appeared in U.S. records. An approved listing does not establish which product a particular pharmacy currently stocks. For Staxyn’s history, use the brand-history page; for ordinary tablet instructions, use the standard administration guide.
The oral-disintegrating form is a manufactured tablet designed to break apart in the mouth rather than being swallowed as an intact film-coated tablet. This does not make it an OTC product, an oral jelly or an imported flavored formulation. U.S. ODT labeling is specific to the approved product and the 10 mg tablet.
A patient should check the pharmacist’s final label and dosage form, not merely the active-ingredient name in an order summary. A medicine described as “vardenafil 10 mg” without a dosage-form field may be ambiguous. An authentic generic ODT has its own package labeling and application status.
U.S. ODT prescribing information states that orally disintegrating vardenafil is not interchangeable with 10 mg film-coated vardenafil. The underlying reason is higher systemic exposure from the dissolving tablet. These are product-level differences, not claims that one is clinically superior.
Neither a pharmacy counter nor a patient should automatically swap formulations because an electronic prescription shows the same nominal strength. If a different dose of vardenafil is needed, the prescriber must choose an appropriate product. The dosing framework covers label considerations without personal dose selection.
| Feature | Vardenafil 10 mg ODT | Film-coated vardenafil tablet |
|---|---|---|
| Form | Dissolves on the tongue | Swallowed as a conventional tablet |
| Named strength | 10 mg ODT presentation | Multiple labeled tablet strengths |
| Systemic exposure | Higher versus film-coated 10 mg in label studies | Different pharmacokinetic exposure |
| Administration | Place on tongue; no liquid | Swallow under prescribed instructions |
| Substitution | Not interchangeable with film-coated 10 mg | Not a direct substitute for ODT |
| Historic U.S. branding | Staxyn (discontinued brand) | Levitra (discontinued brand) |
Labeling directs the ODT to be removed from its blister immediately before use and placed on the tongue to disintegrate. It is taken without liquid and may be used with or without food. In one generic ODT pharmacokinetic study, swallowing with water reduced measured overall exposure (AUC) by about 29%; this is one reason the product instructions should not be replaced by ordinary tablet-taking habits. This is a formulation-specific instruction; it does not authorize chewing unrelated film-coated products or using another medicine as an ODT.
The prescribing information describes as-needed treatment approximately 60 minutes before sexual activity, with sexual stimulation required for an ED response. A clinician determines whether the ODT is suitable; no person should add an ODT to an existing film-coated tablet regimen.
Because the ODT provides different exposure, its prescribing information has restrictions that cannot be assumed identical to every film-coated tablet instruction. The U.S. ODT label directs patients not to use this dosage form with moderate or strong CYP3A4 inhibitors; it also directs against ODT use in moderate or severe hepatic impairment (Child-Pugh B/C) and in patients on renal dialysis. These are stronger, formulation-specific limitations than a generic suggestion to review the medicine list.
Vardenafil in either form is contraindicated with nitrates and riociguat, and QT-related warnings remain relevant. The clinician and pharmacist need the full medication list, not just the current ED prescription. The interaction guide addresses these classes in detail.
Staxyn historically denoted a 10 mg branded oral-disintegrating vardenafil product in the U.S. Original brand marketing has been discontinued. Some current or more recent records concern generic vardenafil ODT and must be checked independently in FDA drug-approval data and product labeling.
The presence of an archived Staxyn NDC or older search snippet does not establish brand availability. Likewise, a generic label does not prove a pharmacy carries inventory. The pharmacy availability page separates current stock inquiries from the legal and regulatory status of a product.
A historical Staxyn label reported 1.01 mg phenylalanine per 10 mg tablet from aspartame and listed sorbitol among its inactive ingredients. A separately published U.S. generic vardenafil ODT label (revised January 2025) instead reports 3.36 mg phenylalanine per tablet and specifically states that the formulation does not contain sorbitol. These details demonstrate why an old brand insert must not be copied onto a distinct generic presentation.
Phenylalanine content is relevant for people with phenylketonuria, while sorbitol content may matter in hereditary fructose intolerance. The information applies to those identified labels, not every possible ODT made by every applicant. Before dispensing, a pharmacist should review the actual product’s inactive ingredients and warnings rather than infer them from the active ingredient, strength or discontinued brand name.
| Formulation record | Phenylalanine statement | Sorbitol statement |
|---|---|---|
| Historical Staxyn 10 mg label | 1.01 mg per tablet | Contains sorbitol |
| One U.S. generic vardenafil ODT 10 mg label (2025) | 3.36 mg per tablet | Label states no sorbitol |
| Another ODT product | Check its own approved label | Do not infer from brand history |
Online foreign-market sellers may advertise flavored jellies, soft tablets, mouth-dissolving forms or high-strength combinations under unrelated trade names. Those descriptions are not evidence that the products follow the FDA-approved ODT application, composition or instructions.
ODT identity requires an actual approved product record, a validated ingredient claim and specific directions. A seller’s use of “dissolving” or “fast acting” does not establish therapeutic equivalence, onset superiority, manufacturing quality or legitimate U.S. distribution.
The labeled U.S. ODT may be taken with or without food. Its tablet design does not guarantee a quicker clinical effect in every person, and pharmacokinetic measurements should not be interpreted as a stopwatch for an erection. Sexual stimulation and individual circumstances remain important.
Food-related effects for standard film-coated tablets belong to their own labeling and should not be copied across formulations. See meal-effect context and onset explanations for the distinct subjects.
An approved application establishes a drug’s regulatory status; an NDC identifies a listed drug product or package and is not by itself evidence that FDA evaluated or approved a particular claim. Neither source confirms inventory at an individual pharmacy on the day of an order.
Ask a licensed pharmacist for the precise product label, current source and applicable substitution policy. The generic vardenafil guide explains how to read approved-product information before making a pharmacy decision.
Confirm that the prescription specifically identifies the desired formulation, that the dispensing pharmacy is licensed and that the medicine supplied matches the authorized record. If the blister is damaged, the formulation differs from the prescription or the label lacks a clear product identity, contact the pharmacist before use.
Unusual symptoms such as fainting, chest pain, sudden vision or hearing changes or an erection lasting more than four hours require appropriate urgent care. Tell emergency clinicians about recent vardenafil exposure because nitrate decisions can be dangerous. The nitrate safety page explains the contraindication.
It is a prescription orally disintegrating form of vardenafil, labeled as a 10 mg tablet that dissolves on the tongue.
The products are not interchangeable. The ODT provides higher systemic exposure and has separate labeling.
U.S. labeling directs placing the tablet on the tongue and taking it without liquid.
No. Dissolving in the mouth does not establish faster clinical onset or superior results.
Staxyn was the historical branded ODT. Original U.S. brand marketing was discontinued; generic ODT products require independent verification.
The U.S. ODT label permits administration with or without food.
No such conclusion follows from a seller’s description. Product-specific FDA approval and substitution status must be verified.
Yes. Nitrates and riociguat are contraindicated. The 10 mg ODT label also directs avoidance of moderate or strong CYP3A4 inhibitors, moderate/severe liver impairment and renal dialysis, and includes a QT-related warning. Confirm the exact product.